FAQ

LRRK2-IN1

Known as: LRRK2-IN-1 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2011-2017
02420112017

Related topics

Related topics

2 relations

Broader (2)

BenzodiazepinonesPyrimidines

Related mentions per year

Related mentions per year

1936-2018
19401960198020002020
LRRK2-IN1
Pyrimidines
Benzodiazepinones

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
No Dopamine Cell Loss or Changes in Cytoskeleton Function in Transgenic Mice Expressing Physiological Levels of Wild Type or G2019S Mutant LRRK2 and in Human Fibroblasts
Mutations within the LRRK2 gene have been identified in Parkinson's disease (PD) patients and have been implicated in the… (More)
Is this relevant?
2014
2014
Small molecule kinase inhibitor LRRK2-IN-1 demonstrates potent activity against colorectal and pancreatic cancer through inhibition of doublecortin-like kinase 1
Doublecortin-like kinase 1 (DCLK1) is emerging as a tumor specific stem cell marker in colorectal and pancreatic cancer. Previous… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2014
2014
Phosphoproteomic evaluation of pharmacological inhibition of leucine-rich repeat kinase 2 reveals significant off-target effects of LRRK-2-IN-1.
Genetic mutations in leucine-rich repeat kinase 2 (LRRK2) have been linked to autosomal dominant Parkinson's disease. The most… (More)
Is this relevant?
2014
2014
Abnormal visual gain control in a Parkinson's disease model
Our understanding of Parkinson's disease (PD) has been revolutionized by the discovery of disease-causing genetic mutations. The… (More)
  • figure 2
  • figure 3
  • figure 4
  • figure 5
  • figure 6
Is this relevant?
2014
2014
The LRRK2 inhibitor GSK2578215A induces protective autophagy in SH-SY5Y cells: involvement of Drp-1-mediated mitochondrial fission and mitochondrial-derived ROS signaling
Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene have been associated with Parkinson’s disease, and its inhibition… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2013
2013
Identification of protein phosphatase 1 as a regulator of the LRRK2 phosphorylation cycle.
A cluster of phosphorylation sites in LRRK2 (leucine-rich repeat kinase 2), including Ser910, Ser935, Ser955 and Ser973, is… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2013
2013
Kinase inhibitors arrest neurodegeneration in cell and C. elegans models of LRRK2 toxicity.
Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most frequent known cause of late-onset Parkinson's disease (PD). To… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2013
2013
Leucine-rich repeat kinase 2 functionally interacts with microtubules and kinase-dependently modulates cell migration.
Recent studies indicate that the Parkinson's disease-linked leucine-rich repeat kinase 2 (LRRK2) modulates cytoskeletal functions… (More)
Is this relevant?
2012
2012
Phosphorylation of LRRK2 serines 955 and 973 is disrupted by Parkinson's disease mutations and LRRK2 pharmacological inhibition.
Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common cause of familial Parkinson's disease. An amino terminal… (More)
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Characterization of a selective inhibitor of the Parkinson’s disease kinase LRRK2
Mutations in leucine-rich repeat kinase 2 (LRRK2) are strongly associated with late-onset autosomal dominant Parkinson's disease… (More)
  • figure 1
  • figure 2
  • figure 3
Is this relevant?